Trifluoperazine

Trifluoperazine is a phenothiazine antipsychotic with a piperazine side chain that produces high-potency dopamine D2 receptor blockade in the mesolimbic pathway, suppressing positive symptoms of psychosis. The trifluoromethyl group enhances D2 receptor affinity relative to low-potency phenothiazines, resulting in effective antipsychotic activity at lower doses but with increased risk of acute extrapyramidal side effects (dystonia, akathisia, parkinsonism) and tardive dyskinesia with chronic use.

Adult

For Schizophrenia and other psychoses: Initially 5 mg twice daily, daily dose may be increased by 5 mg after 1 week. If necessary, dose may be further increased in steps of 5 mg at intervals of 3 days. When satisfactory control has been achieved, reduce gradually until an effective maintenance level has been established.…

Renal adjustment

Start with small doses in severe renal impairment because of increased cerebral sensitivity.

Hepatic adjustment

Manufacturer advises avoid.

Geriatric

For Schizophrenia and other psychoses: Initially up to 2.5 mg twice daily, daily dose may be increased by 5 mg after 1 week. If necessary, dose may be further increased in steps of 5 mg at intervals of 3 days. When satisfactory control has been achieved, reduce gradually until an effective maintenance level has been established.…

Max dose

6 mg per day (for severe nausea and vomiting)

• CNS depression
• Comatose states
• Phaeochromocytoma
• Use in elderly dementia patients (increased mortality risk)